Aclaris shareholders approve doubling authorized shares to 400M and new equity plan with 25.6M reserve

Aclaris Therapeutics, Inc.

Authorized common shares increased from 200M to 400M via Certificate of Amendment effective June 5, 2025; approved by ~96% of votes.
2025 Equity Incentive Plan approved with 25,556,247 share reserve (9M new shares plus rollover from prior plan).
Directors elected: Neal Walker (71.9M for), Andrew Schiff (71.7M for), William Humphries (56.7M for, 15.99M withheld).
Advisory vote on named executive officer compensation passed 55.5M to 16.98M; PwC ratified as auditor for FY2025.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Aclaris Therapeutics, Inc.: Increased authorized common stock from 200,000,000 to 400,000,000 shares (effective 2025-06-05).

Change: charter amendment
Effective: 2025-06-05

Exact text from the filing

the stockholders of the Company approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 200,000,000 shares to 400,000,000 shares

View on SEC.gov

Browse all governance changes →

Aclaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-25-008430

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.